In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BNP: Can Competitors Catch Up to Biosite?

Executive Summary

Biosite has spent the last year building demand for its point-of-care testing (POCT) cardiac marker for chronic heart failure, BNP. The test is poised to be a major successs for Biosite, not least because it has semi-exclusive licensing rights (from Scios), which limit competition and because of the perceived value of its clinical utility. It could be a major victory for a small POCT company. But for Biosite, the hard part is just beginning as competition surfaces from other licensees and similar markers. Most immediately, Roche just launched a similar marker and is gearing up for battle.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts